1. Home
  2. MRCC vs INBX Comparison

MRCC vs INBX Comparison

Compare MRCC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$4.62

Market Cap

135.8M

Sector

Finance

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$68.74

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
INBX
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.8M
1.1B
IPO Year
2011
2024

Fundamental Metrics

Financial Performance
Metric
MRCC
INBX
Price
$4.62
$68.74
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
155.4K
133.7K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
14.85%
N/A
EPS Growth
N/A
649.90
EPS
N/A
N/A
Revenue
N/A
$200,000.00
Revenue This Year
N/A
$563.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.11
$10.81
52 Week High
$7.99
$94.57

Technical Indicators

Market Signals
Indicator
MRCC
INBX
Relative Strength Index (RSI) 33.74 39.32
Support Level N/A $28.54
Resistance Level $6.91 $85.97
Average True Range (ATR) 0.32 4.31
MACD -0.08 -0.73
Stochastic Oscillator 26.23 10.57

Price Performance

Historical Comparison
MRCC
INBX

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: